ACTRN12618001394235
Recruiting
未知
A Randomised Double-blind Placebo-controlled Pilot Study of Intravenous Immunoglobulin Replacement therapy in Lung Transplantation
The Alfred Hospital0 sites40 target enrollmentAugust 20, 2018
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Transplantation
- Sponsor
- The Alfred Hospital
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male and female aged greater than or equal to 18 years
- •Undergoing single lung transplant, bilateral sequential lung transplant (BSLT) or heart\-lung transplant (HLT)
- •Able to give written informed consent
- •Able to understand and comply with all trial requirements
Exclusion Criteria
- •Known allergy to IVIg
- •Active treatment for acute cellular or antibody mediated rejection
- •Known history of severe selective IgA deficiency (\<5mg/dL)
- •Patients who have received IVIg pre\- or post –transplant for any medical indication
- •History of non\-provoked thrombotic events in preceding 3 months
- •LTx recipients who are not followed up long\-term at Alfred Health
- •Re\-transplant
- •Hospitalisation requiring intubation or mechanical ventilation at the time of enrolment.
- •Any other severe condition which in the investigator’s judgment may interfere with the trial evaluations or severely compromise patient safety
- •Currently involved in another investigational interventional trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
Evaluating The desired effect Of the drug Imeglimin In Patients With Polycystic Ovarian SyndromeCTRI/2024/06/068921Riya Sharma self
Completed
Not Applicable
A pilot study of D-cycloserine-augmented cognitive behavioural therapy (CBT) with exposure therapy in adolescents with obsessive-compulsive disorder (OCD)Obsessive-compulsive disorderMental and Behavioural DisordersISRCTN70977225Institute of Psychiatry, Kings College London (UK)24
Active, not recruiting
Phase 1
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorderEUCTR2008-006947-38-GBKing's College London (Institute of Pyschiatry)24
Active, not recruiting
Phase 1
Trial of oxytocin for the treatment of emotional withdrawal symptoms and for relapse prevention in abstinent heroin dependent individualsOpioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individuals experience following detoxification.MedDRA version: 20.0 Level: LLT Classification code 10057379 Term: Addiction relapse System Organ Class: 100000004873MedDRA version: 20.0 Level: LLT Classification code 10001126 Term: Addiction any drug System Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2014-002708-26-GBniversity of Surrey3
Not yet recruiting
Phase 3
The Myer Foundation Study into Multiple SclerosisRelapsing remitting multiple sclerosisNeurological - Multiple sclerosisACTRN12606000359538Melbourne Health20